NRx Pharmaceuticals (NRXP) Competitors $2.69 +0.05 (+1.89%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$2.78 +0.09 (+3.16%) As of 08/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. GNFT, MDWD, RAPT, NLTX, OGI, EPRX, KRRO, TNYA, ENGN, and TILShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include GENFIT (GNFT), MediWound (MDWD), Rapt Therapeutics (RAPT), Neoleukin Therapeutics (NLTX), Organigram Global (OGI), Eupraxia Pharmaceuticals (EPRX), Korro Bio (KRRO), Tenaya Therapeutics (TNYA), enGene (ENGN), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors GENFIT MediWound Rapt Therapeutics Neoleukin Therapeutics Organigram Global Eupraxia Pharmaceuticals Korro Bio Tenaya Therapeutics enGene Instil Bio GENFIT (NASDAQ:GNFT) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Is GNFT or NRXP more profitable? Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A NRx Pharmaceuticals N/A N/A -550.94% Does the media prefer GNFT or NRXP? In the previous week, GENFIT had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 10 mentions for GENFIT and 9 mentions for NRx Pharmaceuticals. GENFIT's average media sentiment score of 1.00 beat NRx Pharmaceuticals' score of -0.13 indicating that GENFIT is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GENFIT 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in GNFT or NRXP? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.2% of GENFIT shares are owned by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, GNFT or NRXP? GENFIT has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do analysts rate GNFT or NRXP? GENFIT currently has a consensus price target of $9.00, suggesting a potential upside of 115.05%. NRx Pharmaceuticals has a consensus price target of $28.50, suggesting a potential upside of 959.48%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has stronger earnings and valuation, GNFT or NRXP? GENFIT has higher revenue and earnings than NRx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.73$1.63MN/AN/ANRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.20 SummaryNRx Pharmaceuticals beats GENFIT on 7 of the 12 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.30M$2.54B$5.82B$9.74BDividend YieldN/A1.68%4.40%4.08%P/E Ratio-1.2022.4130.1425.84Price / SalesN/A541.64435.13105.64Price / CashN/A26.0925.7828.79Price / Book-1.825.529.425.99Net Income-$25.13M$31.83M$3.27B$265.29M7 Day Performance7.17%2.99%3.64%4.07%1 Month Performance-10.33%0.83%3.52%0.93%1 Year Performance41.58%6.16%29.95%18.21% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals3.0606 of 5 stars$2.69+1.9%$28.50+959.5%+29.3%$52.30MN/A-1.202Earnings ReportGNFTGENFIT2.1098 of 5 stars$4.50+12.8%$13.00+188.9%-3.8%$199.51M$76.77M0.00120Positive NewsGap UpHigh Trading VolumeMDWDMediWound1.3796 of 5 stars$17.60-2.8%$32.25+83.2%-7.0%$195.62M$20.22M-6.6780RAPTRapt Therapeutics4.5633 of 5 stars$11.73-0.1%$21.57+83.9%-41.6%$194.15M$1.53M-0.8380NLTXNeoleukin TherapeuticsN/A$20.51+1.5%N/A-42.8%$192.75MN/A-6.5990High Trading VolumeOGIOrganigram Global0.3542 of 5 stars$1.53+7.0%N/A-19.3%$191.66M$117.47M30.61860EPRXEupraxia Pharmaceuticals1.93 of 5 stars$5.30-0.4%$11.00+107.5%+94.0%$191.42MN/A-6.2429Gap UpKRROKorro Bio1.2993 of 5 stars$19.72-2.7%$86.83+340.3%-55.5%$190.26M$2.27M-2.0270TNYATenaya Therapeutics2.5967 of 5 stars$1.26+8.6%$6.25+396.0%-62.5%$189.05MN/A-1.31110Gap UpHigh Trading VolumeENGNenGene3.121 of 5 stars$3.72+1.1%$23.29+526.0%-33.0%$188.07MN/A-2.2531TILInstil Bio3.1265 of 5 stars$28.85+3.6%$119.00+312.5%+89.7%$187.94MN/A-2.23410 Related Companies and Tools Related Companies GENFIT Alternatives MediWound Alternatives Rapt Therapeutics Alternatives Neoleukin Therapeutics Alternatives Organigram Global Alternatives Eupraxia Pharmaceuticals Alternatives Korro Bio Alternatives Tenaya Therapeutics Alternatives enGene Alternatives Instil Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access